SF Wolf, would you not view this as a take it all or nothing type of approach? Tackling the upper end of patients suffering is so much of a stretch given the current level of research on this drug and on success to date by other companies with this disease state that is strikes me as quite extraordinary. Is it just a home run shot by a newcomer taking a low probability attempt at a huge product, or, is it more completely reflective of their high degree of confidence based on all their sound work, which they view as a high probability of success, though without human data just yet.
News 
Market Data 
Discover 
